Advertisement

Dysphagia

, Volume 26, Issue 3, pp 340–343 | Cite as

Risperidone-Induced Bulbar Palsy-like Syndrome

  • Jason Jonathon SicoEmail author
  • Huned Patwa
Case Report

Abstract

There have been several case reports of risperidone-associated dysphagia. Risperidone-induced bulbar palsy-like syndrome has not been previously described. We report on a 58-year-old gentleman with prior history of schizophrenia and remote chlorpromazine use with no history of extrapyramidal symptoms who experienced acute onset of dysphagia and facial diplegia with hyperprolactinemia while being treated with risperidone. To date there have been five reported cases of dysphagia associated with risperidone, occurring by such mechanisms as isolated pharyngeal dysfunction from pharyngeal constrictor palsy and dystonia, drug-induced parkinsonism, and acute dystonic reaction. These cases were associated either with initiation or up-titration of risperidone, with complete resolution of dysphagia after medication discontinuation or dose change. Our patient developed dysphagia within 2 weeks of taking risperidone and completely resolved 1 month after the medication was stopped. Unlike other reported cases, our patient also experienced symptomatic hyperprolactinemia, another known side effect of risperidone. Physicians should also be aware that risperidone can be associated with oropharyngeal dysphagia secondary to an acute bulbar palsy-like syndrome that places patients at increased risk of aspiration events and its associated morbidity and mortality.

Keywords

Dysphagia Oropharyngeal hypomotility Deglutition Deglutition disorders Bulbar palsy Risperidone Hyperprolactinemia Swallowing 

References

  1. 1.
    Saud B, Szyjkowski R. A diagnostic approach to dysphagia. Clin Fam Pract. 2004;6:525–46.CrossRefGoogle Scholar
  2. 2.
    Dziewas R, Warnecke T, Schnabel M, Ritter M, Nabavi DG, Schilling M, Ringelstein EB, Reker T. Neuroleptic-induced dysphagia: case report and literature review. Dysphagia. 2007;22:63–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Janssen Pharmaceutica, Risperdal package insert. Available at http://www.janssen.com/janssen/products.html. Accessed 10 Nov 2008.
  4. 4.
    Pierre J. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28:191–208.PubMedCrossRefGoogle Scholar
  5. 5.
    Reilly T, Kirk M. Atypical antipsychotics and newer antidepressants. Emerg Med Clin N Am. 2007;25:477–97.CrossRefGoogle Scholar
  6. 6.
    Stewart J. Dysphagia associated with risperidone therapy. Dysphagia. 2003;18:274–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Duggal HS, Mendhekar DN. Risperidone-induced tardive pharyngeal dystonia presenting with persistent dysphagia: a case report. Prim Care Companion J Clin Psychiatry. 2008;10:161–2.PubMedCrossRefGoogle Scholar
  8. 8.
    Nair S, Saeed O, Shahab H. Sudden dysphagia with uvular enlargement following the initiation of risperidone which responded to benztropine: was this an extrapyramidal side effect? Gen Hosp Psychiatry 2001;23:231-2.Google Scholar
  9. 9.
    Varghese S, Balhara Y. Risperidone and dysphagia. J Postgrad Med. 2006;52:327–8.PubMedGoogle Scholar
  10. 10.
    Brahm NC, Fast GA, Brown RC. Risperidone and dysphagia in a developmentally disabled woman. Prim Care Companion J Clin Psychiatry. 2007;9:315–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Afzal K, Briones D, DeVargas C. Risperidone-induced polydipsia and polyphagia associated with galactorrhea, abdominal pain, and rapid weight gain in an adolescent hispanic female. CNS Spectr. 2007;12:818–20.PubMedGoogle Scholar
  12. 12.
    Buchholz D. Neurogenic dysphagia: what is the cause when the cause is not obvious? Dysphagia 2004;9:245-55.Google Scholar
  13. 13.
    Fishman S, Wilsey B, Mahajan G, Molina P. Methadone reincarnated: novel clinical applications with related concerns. Pain Med. 2002;3:339–48.PubMedCrossRefGoogle Scholar
  14. 14.
    Solomon K. Phenothiazine-induced bulbar palsy-like syndrome and sudden death. Am J Psychiatry. 1977;134:308–11.PubMedGoogle Scholar
  15. 15.
    Kato D, Kawanishi C, Kishida I, Furuno T, Matsumura T, Hasegawa H, Hirayasu Y. Delirium resolving upon switching from risperidone to quetiapine: implication of CYP2D6 genotype. Psychosomatics. 2005;46:374–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC (outside the USA) 2010

Authors and Affiliations

  1. 1.Department of NeurologyYale University School of MedicineNew HavenUSA
  2. 2.Department of Internal MedicineYale University School of MedicineNew HavenUSA
  3. 3.Veterans Affairs Healthcare SystemWest HavenUSA
  4. 4.Department of NeurologyVA Connecticut Health Care SystemWest HavenUSA

Personalised recommendations